TorrentFreak

DECEMBER 3, 2024

The DISH complaint described Jadoo TV’s operation as a “deliberate, multi-year effort” to distribute its exclusively-licensed TV channels without authorization, amounting to direct, contributory, and vicarious infringement under 17 U.S.C. 20, 2025,” the statement reads. Section 501.

Copyright Infringement 58

Copyright Infringement Settlement Copyright Litigation 58

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Microsoft Technology Licensing LLC v.

Invention 59

Invention Art Trademark Patent Application 59

The IPKat

FEBRUARY 29, 2024

Sony maintains that the worldwide copyright for the recordings is held by Experience Hendrix LLC and Authentic Hendrix LLC, who license the rights to exploit and distribute the recordings to them. It is likely therefore that it will stand to be determined by a High Court judge some time in 2025.

Copyright 109

Copyright Reporting Contracts Settlement 109

SpicyIP

MARCH 15, 2024

This post does not, in any manner, get into the arena of willingness or unwillingness of defendants to enter into a licensing agreement. Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. That is a different matter altogether.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

LexBlog IP

NOVEMBER 5, 2023

Under the IRA, drugs selected for the Program remain “selected drugs” until HHS determines that there is at least one product that is both “approved or licensed” as a generic or biosimilar of the selected drug and “marketed pursuant to such approval or licensure.”

Marketing 40

Marketing Marketing Government Litigation 40

LexBlog IP

JANUARY 25, 2024

FDA Approvals In 2023, there were 23 FDA approvals of Biologic License Applications , including for Vertex’s CASGEVY and Bluebird’s LYFGENIA, the first cell-based gene therapies for the treatment of sickle cell disease. As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023.

Marketing 40

Marketing Marketing Licensing Litigation 40

Patently-O

JULY 31, 2024

They also argue that this has created an environment where large, multinational companies are incentivized to engage in “predatory infringement,” finding it cheaper to infringe patents than to license them, especially when the patent holders are “undercapitalized entities” such as individual, universities, or start-ups.

Patent 53

Patent Patent Infringement Law Settlement 53

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020. No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement.

Litigation 52

Litigation Settlement Marketing Marketing 52

LexBlog IP

FEBRUARY 23, 2024

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech is still awaiting FDA approval of AVT04 in the United States, but has already secured a licensing agreement with Johnson & Johnson for the U.S.

Settlement 40

Settlement Marketing Marketing Licensing 40